Romosozumab Treatment Duration Debate: New Evidence Challenges Practice
Personalized briefing
Discovery of the day · Diabetes
[Correspondence] Treatment duration for romosozumab – Authors’ reply
Dear Dr.Vijay Viswanathan, this is your personalized scientific intelligence briefing — curated for your work in Diabetes.
Key finding
Medicine · Diabetes & Endocrinology
Discovery of the day
The authors of the LIDA study respond to concerns about deviating from the approved 12-month romosozumab treatment course, defending their exploration of alternative durations. They argue that critics place disproportionate emphasis on selected findings and do not fully reflect the breadth of available evidence. For a leading diabetologist managing osteoporosis in older adults with diabetes, this debate underscores the need to critically evaluate treatment protocols that may improve outcomes in patients with complex metabolic comorbidities.
Novelty
72%
Rigor
85%
Significance
83%
Validity
88%
Clarity
91%
Advertisement
ScientificChina — verified Chinese lab & medical equipment suppliers, direct. Browse suppliers →
Your briefing is personalized based on your selected fields, keywords, and research interests.
